Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sonnet Biotherapeutics Holdings Inc (NQ: SONN ) 0.7210 +0.0110 (+1.55%) Streaming Delayed Price Updated: 3:44 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 36,893 Open 0.7160 Bid (Size) 0.7200 (1) Ask (Size) 0.7450 (1) Prev. Close 0.7100 Today's Range 0.7100 - 0.7411 52wk Range 0.6239 - 6.178 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket August 16, 2024 Via Benzinga SONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024 August 14, 2024 SONN stock results show that Sonnet BioTherapeutics beat analyst estimates for earnings per share the third quarter of 2024. Via InvestorPlace Performance YTD -59.03% -59.03% 1 Month -8.15% -8.15% 3 Month -54.08% -54.08% 6 Month -60.17% -60.17% 1 Year -83.61% -83.61% More News Read More Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update August 14, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study July 24, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Pre-Market Session June 21, 2024 Via Benzinga Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher June 20, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 20, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session June 20, 2024 Via Benzinga Gold Rises 1%; Accenture Shares Surge After Q3 Results June 20, 2024 Via Benzinga Dow Edges Lower; US Current Account Deficit Widens In Q1 June 20, 2024 Via Benzinga Topics Stocks Exposures US Equities Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds June 20, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain June 13, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting May 28, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Announces Review of Strategic Alternatives May 22, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target May 20, 2024 Via ACCESSWIRE SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024 May 15, 2024 Via InvestorPlace Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update May 14, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference May 06, 2024 Via ACCESSWIRE Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting March 19, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective March 11, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers February 29, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 14, 2024 Via Benzinga Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update February 14, 2024 Via ACCESSWIRE 12 Health Care Stocks Moving In Tuesday's After-Market Session February 13, 2024 Via Benzinga Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy December 21, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
